Impact of serum leptin and adiponectin levels on brain infarcts in patients with mild cognitive impairment and Alzheimer's disease: a longitudinal analysis.
Alzheimer’s disease
MR imaging
adiponectin
brain infarcts
leptin
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
02
2024
accepted:
27
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
The adipokines leptin and adiponectin have been associated with atherosclerosis and the risk of cerebral infarcts. Pre-clinical studies, however, suggest a protective role against ischemic brain damage. In this study we analyzed the relationship between serum leptin and adiponectin levels and the onset or progression of brain infarcts in subjects with mild cognitive impairment (MCI) and Alzheimer's disease (AD). All data were extracted from the ADNI database. The final population included 566 subjects, with 58 healthy controls, 396 MCI and 112 AD. All patients with available serum leptin and adiponectin levels at baseline were selected. Demographics, neuropsychological test results, CSF biomarkers, regional brain metabolism with FDG-PET data and the number of brain infarcts on longitudinal MRI scans were extracted. Leptin levels were significantly lower in patients with MCI than controls at baseline, while adiponectin levels were not different between the groups. Multivariate logistic regression analysis at baseline for the presence of brain infarcts showed a predictive value for leptin but not for adiponectin. Multivariate longitudinal analysis showed that age was the only significant predictor of brain infarcts development at 15-year follow-up, while serum leptin and adiponectin levels did not play a role in this population. The evidence on the pathogenetic or protective role of adipokines on ischemic brain damage is mixed. In this MCI and AD population, serum leptin and adiponectin were not associated with the development of brain infarcts; therefore, these results do not support the use of adipokines as biomarkers of cerebrovascular pathology in this population.
Identifiants
pubmed: 38686200
doi: 10.3389/fendo.2024.1389014
pmc: PMC11056582
doi:
Substances chimiques
Adiponectin
0
Leptin
0
Biomarkers
0
ADIPOQ protein, human
0
LEP protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1389014Informations de copyright
Copyright © 2024 Carbone, Bencivenga, Santoro, De Lucia, Palaia, Ercolano, Scognamiglio, Edison, Ferrara, Vitale, Rengo and Femminella.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision
Références
Stat Med. 2004 Mar 15;23(5):723-48
pubmed: 14981672
PLoS One. 2019 Nov 8;14(11):e0225008
pubmed: 31703113
Stroke. 2007 Aug;38(8):2329-36
pubmed: 17600230
Gene Ther. 2014 Mar;21(3):298-308
pubmed: 24430238
Neuropharmacology. 2018 Jul 1;136(Pt B):298-306
pubmed: 28987937
Neurobiol Aging. 2009 Sep;30(9):1483-9
pubmed: 18358569
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Noro Psikiyatr Ars. 2018 Jun 05;55(3):211-214
pubmed: 30224865
J Alzheimers Dis. 2014;41(2):525-33
pubmed: 24625795
Front Neurosci. 2019 Jan 14;12:1027
pubmed: 30692905
Stroke. 2008 Mar;39(3):943-50
pubmed: 18239178
Lancet Neurol. 2016 Aug;15(9):934-943
pubmed: 27312738
Alzheimers Dement. 2020 Nov;16(11):1553-1560
pubmed: 31706733
J Cereb Blood Flow Metab. 2013 Apr;33(4):567-74
pubmed: 23299243
Stroke. 2015 Oct;46(10):2881-5
pubmed: 26337973
Front Neurol. 2020 Aug 25;11:927
pubmed: 32982937
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
J Neurosci Rural Pract. 2018 Jul-Sep;9(3):376-380
pubmed: 30069095
Curr Alzheimer Res. 2014 Feb;11(2):165-74
pubmed: 24359504
Metabolism. 2015 Jan;64(1):24-34
pubmed: 25199978
Front Aging Neurosci. 2018 May 15;10:132
pubmed: 29867443
Brain. 2013 Sep;136(Pt 9):2697-706
pubmed: 23842566
Lancet Neurol. 2007 Jul;6(7):611-9
pubmed: 17582361
Curr Opin Lipidol. 2017 Aug;28(4):347-354
pubmed: 28463859
Biochim Biophys Acta. 2016 May;1862(5):966-74
pubmed: 26546479
Alzheimers Dement. 2019 Jan;15(1):158-167
pubmed: 30642436
Am J Med Sci. 2007 Mar;333(3):140-4
pubmed: 17496731
N Engl J Med. 2003 Mar 27;348(13):1215-22
pubmed: 12660385
Int J Nanomedicine. 2019 Jul 19;14:5541-5554
pubmed: 31410002
Cardiovasc Diabetol. 2019 Aug 14;18(1):105
pubmed: 31412946
J Neurosci. 2001 Dec 15;21(24):RC186
pubmed: 11734601
Dis Markers. 2015;2015:450237
pubmed: 26693203
J Neurol. 2003 Sep;250(9):1050-5
pubmed: 14504965
Int J Mol Sci. 2020 Dec 04;21(23):
pubmed: 33291597
JAMA. 1997 Jul 9;278(2):113-4
pubmed: 9214520
Int J Epidemiol. 1999 Oct;28(5):964-74
pubmed: 10597998
Biochim Biophys Acta. 2015 Sep;1852(9):1887-94
pubmed: 26118345
Lancet Neurol. 2014 Sep;13(9):913-23
pubmed: 25142458
J Alzheimers Dis. 2020;76(4):1179-1198
pubmed: 32597813
Cerebrovasc Dis. 2003;15(1-2):63-9
pubmed: 12499713
Lancet Neurol. 2003 Jun;2(6):335
pubmed: 12849148
PLoS One. 2017 Dec 21;12(12):e0186205
pubmed: 29267309
Am J Physiol Cell Physiol. 2002 Jul;283(1):C244-50
pubmed: 12055093
Ann N Y Acad Sci. 2002 Jun;967:379-88
pubmed: 12079865
PLoS One. 2019 Sep 26;14(9):e0216507
pubmed: 31557186